⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL765716 | 1.00 | — | — | |
| SCHEMBL5369505 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL3934119 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL755298 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL3931726 | 0.96 | — | — | |
| SCHEMBL21921142 | 0.75 | — | — | |
| SCHEMBL586900 | 0.75 | — | — | |
| SCHEMBL11056284 | 0.73 | — | — | |
| SCHEMBL23776843 | 0.72 | — | — | |
| SCHEMBL10002484 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4371987-B9 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4371987-B1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250270190-A1 | KIT INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-08-28 | — | — | US | disclosed |
| EP-4578451-A2 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | Novartis AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| EP-4214210-B1 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | NOVARTIS AG (CH) | 2025-04-09 | — | — | EP | disclosed |
| US-12258346-B2 | Substituted 6-azabenzimidazole compounds | GILEAD SCIENCES, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240299387-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | BLUEPRINT MEDICINES CORPORATION | 2024-09-12 | — | — | US | disclosed |
| US-20240287061-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2024-08-29 | — | — | US | disclosed |
| US-20240270724-A1 | GALECTIN-3 INHIBITING C-GLYCOSIDES | GLYCOMIMETICS, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| CN-113227089-B | Substituted 6-azabenzimidazole compounds as HPK1 inhibitors | 吉利德科学公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20230190763-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-06-22 | — | — | US | disclosed |
| WO-2022241183-A1 | GALECTIN-3 INHIBITING C-GLYCOSIDES | GLYCOMIMETICS, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| US-20220213091-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2022-07-07 | — | — | US | disclosed |
| US-20220160725-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2022-05-26 | — | — | US | disclosed |
| US-11203591-B2 | Substituted 6-azabenzimidazole compounds | GILEAD SCIENCES, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| EP-3873903-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-09-08 | — | — | EP | disclosed |
| CN-113227089-A | Substituted 6-azabenzimidazole compounds as HPK1 inhibitors | 吉利德科学公司 | 2021-08-06 | — | — | CN | disclosed |
| US-20210115037-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2021-04-22 | — | — | US | disclosed |
| EP-2243769-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE FLUOROAMINE | CENTRAL GLASS CO LTD (JP) | 2017-06-28 | — | — | EP | disclosed |
| EP-2243769-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE FLUOROAMINE | Central Glass Company, Limited (JP) | 2010-10-27 | — | — | EP | disclosed |